BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26924081)

  • 1. Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck.
    Linares J; Rullan A; Taberna M; Vazquez S; Mesia R
    Oral Oncol; 2016 Apr; 55():e4. PubMed ID: 26924081
    [No Abstract]   [Full Text] [Related]  

  • 2. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.
    Bowles DW; Keysar SB; Eagles JR; Wang G; Glogowska MJ; McDermott JD; Le PN; Gao D; Ray CE; Rochon PJ; Roop DR; Tan AC; Serracino HS; Jimeno A
    Oral Oncol; 2016 Feb; 53():74-9. PubMed ID: 26705064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
    Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.
    Sukari A; Nagasaka M; Diab M; Al Sibai K; Atassi B; Elayoubi JA; Kim S; Küçük Ö
    Clin Otolaryngol; 2019 Jul; 44(4):639-643. PubMed ID: 30784192
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
    Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
    Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable complete remission induced by cetuximab monotherapy in a patient infected with HIV and diagnosed with recurrent squamous cell carcinoma of the head and neck.
    Rubinstein PG; Lindgren V; Setty S; Yao M; Pytynia KB; Radosevich JA; Kadkol SS; Feldman LE
    J Clin Oncol; 2011 Mar; 29(9):e222-5. PubMed ID: 21189379
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.
    Madoz-Gúrpide J; Zazo S; Chamizo C; Casado V; Caramés C; Gavín E; Cristóbal I; García-Foncillas J; Rojo F
    J Transl Med; 2015 Aug; 13():282. PubMed ID: 26319934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-arterial cetuximab for the treatment of recurrent unresectable head and neck squamous cell carcinoma
    Tham T; White TG; Chakraborty S; Lall RR; Ortiz R; Langer DJ; Shatzkes D; Filippi CG; Kraus D; Boockvar JA; Costantino PD
    J Exp Ther Oncol; 2016 Nov; 11(4):293-301. PubMed ID: 27849340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma.
    Quan K; Xu KM; Zhang Y; Clump DA; Flickinger JC; Lalonde R; Burton SA; Heron DE
    Semin Radiat Oncol; 2016 Apr; 26(2):112-9. PubMed ID: 27000507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
    Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
    Massa E; Dessì M; Gaspardini G; Saba F; Cherchi V; Mantovani G
    Oral Oncol; 2010 Nov; 46(11):818-21. PubMed ID: 20920877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell cancer].
    Vladimirova LY; Agieva AA; Engibaryan MA
    Vopr Onkol; 2015; 61(4):580-2. PubMed ID: 26571826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.
    Comet B; Kramar A; Faivre-Pierret M; Dewas S; Coche-Dequeant B; Degardin M; Lefebvre JL; Lacornerie T; Lartigau EF
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):203-9. PubMed ID: 22331006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
    Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
    Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
    J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
    J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.